These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 23401230)

  • 1. A cost savings approach to SPRED1 mutational analysis in individuals at risk for neurofibromatosis type 1.
    Muram TM; Stevenson DA; Watts-Justice S; Viskochil DH; Carey JC; Mao R; Jackson B
    Am J Med Genet A; 2013 Mar; 161A(3):467-72. PubMed ID: 23401230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome.
    Messiaen L; Yao S; Brems H; Callens T; Sathienkijkanchai A; Denayer E; Spencer E; Arn P; Babovic-Vuksanovic D; Bay C; Bobele G; Cohen BH; Escobar L; Eunpu D; Grebe T; Greenstein R; Hachen R; Irons M; Kronn D; Lemire E; Leppig K; Lim C; McDonald M; Narayanan V; Pearn A; Pedersen R; Powell B; Shapiro LR; Skidmore D; Tegay D; Thiese H; Zackai EH; Vijzelaar R; Taniguchi K; Ayada T; Okamoto F; Yoshimura A; Parret A; Korf B; Legius E
    JAMA; 2009 Nov; 302(19):2111-8. PubMed ID: 19920235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPRED 1 mutations in a neurofibromatosis clinic.
    Muram-Zborovski TM; Stevenson DA; Viskochil DH; Dries DC; Wilson AR; Rong Mao
    J Child Neurol; 2010 Oct; 25(10):1203-9. PubMed ID: 20179001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SPRED1 germline mutations caused a neurofibromatosis type 1 overlapping phenotype.
    Pasmant E; Sabbagh A; Hanna N; Masliah-Planchon J; Jolly E; Goussard P; Ballerini P; Cartault F; Barbarot S; Landman-Parker J; Soufir N; Parfait B; Vidaud M; Wolkenstein P; Vidaud D; France RN
    J Med Genet; 2009 Jul; 46(7):425-30. PubMed ID: 19366998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive RNA Analysis of the NF1 Gene in Classically Affected NF1 Affected Individuals Meeting NIH Criteria has High Sensitivity and Mutation Negative Testing is Reassuring in Isolated Cases With Pigmentary Features Only.
    Evans DG; Bowers N; Burkitt-Wright E; Miles E; Garg S; Scott-Kitching V; Penman-Splitt M; Dobbie A; Howard E; Ealing J; Vassalo G; Wallace AJ; Newman W; ; Huson SM
    EBioMedicine; 2016 May; 7():212-20. PubMed ID: 27322474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPRED1 mutations (Legius syndrome): another clinically useful genotype for dissecting the neurofibromatosis type 1 phenotype.
    Spurlock G; Bennett E; Chuzhanova N; Thomas N; Jim HP; Side L; Davies S; Haan E; Kerr B; Huson SM; Upadhyaya M
    J Med Genet; 2009 Jul; 46(7):431-7. PubMed ID: 19443465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NF1 exon 22 analysis of individuals with the clinical diagnosis of neurofibromatosis type 1.
    Muram-Zborovski TM; Vaughn CP; Viskochil DH; Hanson H; Mao R; Stevenson DA
    Am J Med Genet A; 2010 Aug; 152A(8):1973-8. PubMed ID: 20602485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Legius syndrome, an Update. Molecular pathology of mutations in SPRED1.
    Brems H; Legius E
    Keio J Med; 2013; 62(4):107-12. PubMed ID: 24334617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The first Slovak Legius syndrome patient carrying the SPRED1 gene mutation.
    Sekelska M; Briatkova L; Olcak T; Bolcekova A; Ilencikova D; Kadasi L; Zatkova A
    Gen Physiol Biophys; 2017 Apr; 36(2):205-210. PubMed ID: 28150585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanding the Noonan spectrum/RASopathy NGS panel: Benefits of adding NF1 and SPRED1.
    Witkowski L; Dillon MW; Murphy E; S Lebo M; Mason-Suares H
    Mol Genet Genomic Med; 2020 Apr; 8(4):e1180. PubMed ID: 32107864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding the phenotype of a neurofibromatosis type 1-like syndrome: a patient with a SPRED1 mutation and orbital manifestations.
    Lane KA; Anninger WV; Katowitz JA
    Ophthalmic Plast Reconstr Surg; 2009; 25(5):399-401. PubMed ID: 19966658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutional mismatch repair deficiency as a differential diagnosis of neurofibromatosis type 1: consensus guidelines for testing a child without malignancy.
    Suerink M; Ripperger T; Messiaen L; Menko FH; Bourdeaut F; Colas C; Jongmans M; Goldberg Y; Nielsen M; Muleris M; van Kouwen M; Slavc I; Kratz C; Vasen HF; Brugiѐres L; Legius E; Wimmer K
    J Med Genet; 2019 Feb; 56(2):53-62. PubMed ID: 30415209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SPRED1, a RAS MAPK pathway inhibitor that causes Legius syndrome, is a tumour suppressor downregulated in paediatric acute myeloblastic leukaemia.
    Pasmant E; Gilbert-Dussardier B; Petit A; de Laval B; Luscan A; Gruber A; Lapillonne H; Deswarte C; Goussard P; Laurendeau I; Uzan B; Pflumio F; Brizard F; Vabres P; Naguibvena I; Fasola S; Millot F; Porteu F; Vidaud D; Landman-Parker J; Ballerini P
    Oncogene; 2015 Jan; 34(5):631-8. PubMed ID: 24469042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neurofibromatosis type 1 molecular diagnosis: what can NGS do for you when you have a large gene with loss of function mutations?
    Pasmant E; Parfait B; Luscan A; Goussard P; Briand-Suleau A; Laurendeau I; Fouveaut C; Leroy C; Montadert A; Wolkenstein P; Vidaud M; Vidaud D
    Eur J Hum Genet; 2015 May; 23(5):596-601. PubMed ID: 25074460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and molecular characterization of 112 single-center patients with Neurofibromatosis type 1.
    Corsello G; Antona V; Serra G; Zara F; Giambrone C; Lagalla L; Piccione M; Piro E
    Ital J Pediatr; 2018 Apr; 44(1):45. PubMed ID: 29618358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurofibromatosis type I: mutation spectrum of NF1 in spanish patients.
    Palma Milla C; Lezana Rosales JM; López Montiel J; Andrés Garrido LD; Sánchez Linares C; Carmona Tamajón S; Torres Fernández C; Sánchez González P; Franco Freire S; Benito López C; López Siles J
    Ann Hum Genet; 2018 Nov; 82(6):425-436. PubMed ID: 30014477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype.
    Brems H; Chmara M; Sahbatou M; Denayer E; Taniguchi K; Kato R; Somers R; Messiaen L; De Schepper S; Fryns JP; Cools J; Marynen P; Thomas G; Yoshimura A; Legius E
    Nat Genet; 2007 Sep; 39(9):1120-6. PubMed ID: 17704776
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Family with Legius syndrome (neurofibromatosis type 1-like syndrome).
    Sakai N; Maeda T; Kawakami H; Uchiyama M; Harada K; Tsuboi R; Mitsuhashi Y
    J Dermatol; 2015 Jul; 42(7):703-5. PubMed ID: 25981987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic diagnosis of neurofibromatosis type 1: targeted next- generation sequencing with Multiple Ligation-Dependent Probe Amplification analysis.
    Wu-Chou YH; Hung TC; Lin YT; Cheng HW; Lin JL; Lin CH; Yu CC; Chen KT; Yeh TH; Chen YR
    J Biomed Sci; 2018 Oct; 25(1):72. PubMed ID: 30290804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel association of neurofibromatosis type 1-causing mutations in families with neurofibromatosis-Noonan syndrome.
    Ekvall S; Sjörs K; Jonzon A; Vihinen M; Annerén G; Bondeson ML
    Am J Med Genet A; 2014 Mar; 164A(3):579-87. PubMed ID: 24357598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.